BioAtla (BCAB) Net Cash Flow (2020 - 2026)

BioAtla's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$5.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 69.09% year-over-year to -$5.2 million in Q1 2026; TTM through Mar 2026 was -$30.4 million, a 37.01% increase from a year earlier, with the FY2025 full-year figure at -$41.9 million, up 32.83% from the prior year.
• Net Cash Flow retreated to -$5.2 million in Q1 2026 per BCAB's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $37.4 million in Q4 2022 and bottomed at -$30.8 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$17.1 million (2022), against an average of -$14.3 million.
• Across the five-year window, Net Cash Flow surged 249.87% in 2022 and slumped 179.74% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at $37.4 million in 2022, then slumped by 179.74% to -$29.8 million in 2023, then jumped by 74.94% to -$7.5 million in 2024, then soared by 83.91% to -$1.2 million in 2025, then plunged by 329.03% to -$5.2 million in 2026.
• Per Business Quant, the three latest BCAB Net Cash Flow figures stand at -$5.2 million (Q1 2026), -$1.2 million (Q4 2025), and -$9.9 million (Q3 2025).